Shanghai Aisair Biotechnology

Shanghai Aisair Biotechnology is a clinical-stage biotechnology company dedicated to the development of next-generation, "off-the-shelf" cell therapies using induced pluripotent stem cell (iPSC) technology. The company's proprietary Ais-iPSC platform enables the efficient reprogramming and large-scale differentiation of iPSCs into various immune cell types, including natural killer (NK) cells and T cells. Aisair's lead candidate, AS-01, is an iPSC-derived NK cell therapy currently in Phase 1 clinical trials for the treatment of advanced solid tumors. The company is also advancing a pipeline of chimeric antigen receptor (CAR)-engineered iNK cells (CAR-iNK) designed to target specific antigens in hematological and solid malignancies. Based in Shanghai, Aisair integrates gene editing, cell reprogramming, and GMP-compliant manufacturing to provide scalable and accessible immunotherapy solutions.